Since hypoadiponectinemia is a major symptom of diverse human metabolic diseases such as obesity, type 2 diabetes, atherosclerosis, and non-alcoholic steatohepatitis, compounds that stimulate adiponectin secretion could be promising for the treatment of metabolic diseases such as T2DM. This evidence concerns the gene ADIPOQ and metabolic disease.